We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

70 hedge funds and large institutions have $251M invested in Progenics Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

3% less capital invested

Capital invested by funds: $258M → $251M (-$6.61M)

16% less funds holding

Funds holding: 83 → 70 (-13)

64% less call options, than puts

Call options by funds: $484K | Put options by funds: $1.33M

65% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 20

Holders
70
Holders Change
-13
Holders Change %
-15.66%
% of All Funds
2.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
23
Reduced
22
Closed
20
Calls
$484K
Puts
$1.33M
Net Calls
-$843K
Net Calls Change
-$346K

Top Buyers

Rank Fund Capital Flow
1
PFC
Phocas Financial Corp
California
+$2.75M
2
BC
Broadfin Capital
New York
+$2.29M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$545K
4
JG
Jefferies Group
New York
+$532K
5
BIT
BlackRock Institutional Trust
California
+$506K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$11.4M
2
HCMT
Highland Capital Management (Texas)
Texas
-$3.17M
3
Morgan Stanley
Morgan Stanley
New York
-$1.82M
4
BIM
Bogle Investment Management
Massachusetts
-$1.7M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
BIM
26
BlackRock Investment Management
Delaware
$914K -$12.1K -2,742 -2%
JG
27
Jefferies Group
New York
$831K +$532K +120,900 +345%
TC
28
TFS Capital
Pennsylvania
$825K -$172K -39,167 -20%
Bank of America
29
Bank of America
North Carolina
$791K +$148K +33,543 +29%
Goldman Sachs
30
Goldman Sachs
New York
$606K +$122K +27,636 +32%
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$575K +$2.2K +500 +0.5%
Citadel Advisors
32
Citadel Advisors
Florida
$512K -$257K -58,430 -38%
MCM
33
Moore Capital Management
New York
$506K +$198K +45,000 +90%
Millennium Management
34
Millennium Management
New York
$467K +$385K +87,535 New
Charles Schwab
35
Charles Schwab
California
$453K – – –
TA
36
Teachers Advisors
New York
$416K +$14.4K +3,280 +4%
BCM
37
Bridgeway Capital Management
Texas
$386K – – –
HK
38
Horizon Kinetics
New York
$358K – – –
MLICM
39
Metropolitan Life Insurance Company (MetLife)
New York
$343K +$102K +23,250 +56%
AQR Capital Management
40
AQR Capital Management
Connecticut
$306K +$253K +57,500 New
PPA
41
Parametric Portfolio Associates
Washington
$305K +$252K +57,219 New
Barclays
42
Barclays
United Kingdom
$296K +$103K +23,380 +65%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$287K – – –
NFA
44
Nationwide Fund Advisors
Ohio
$247K -$115K -26,033 -36%
AllianceBernstein
45
AllianceBernstein
Tennessee
$244K -$45.3K -10,300 -18%
State Board of Administration of Florida Retirement System
46
State Board of Administration of Florida Retirement System
Florida
$242K – – –
VOYA Investment Management
47
VOYA Investment Management
Georgia
$241K – – –
Group One Trading
48
Group One Trading
Illinois
$222K -$3.73K -847 -2%
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$219K – – –
BA
50
BlackRock Advisors
Delaware
$218K +$15.4K +3,505 +9%
1
2
3 4

PGNX Hedge Fund Activity: Q4 2013 in Review

70 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2013, worth a combined $251M — down 2.6% from $258M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of PGNX and 7 opened new positions — a net loss of 13 holders — while 22 trimmed existing stakes and 23 added.

The largest buyer was Phocas Financial Corp, opening a new position worth an estimated $2.75M. The largest seller was Fidelity Investments, cutting an estimated $11.4M.

  • 70 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2013, down from 83 in Q3 2013.
  • Funds reported $251M of Progenics Pharmaceuticals Inc stock for Q4 2013, down 2.6% quarter-over-quarter.
  • 7 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2013 and 20 closed out, a net change of -13 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2013 was Phocas Financial Corp, an estimated $2.75M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2013 was Fidelity Investments, an estimated $11.4M sold.

Based on aggregated 13F filings for Q4 2013.